ABUS
Arbutus Biopharma Corp
5.00$
+0.2%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -82.8% | -220.3% | -3,859.0% | -454.2% | -1,150.8% | -1,181.3% | -744.0% | -614.6% | -90.6% | -473.7% | -1,050.9% | -281.5% | |
| 3.5% | 2.4% | 72.8% | 18.9% | 37.0% | 33.7% | 28.6% | 16.0% | 3.7% | 7.7% | 22.4% | 2.6% | |
| 21.9% | 88.8% | 2,610.6% | 141.3% | 105.8% | 113.1% | 89.1% | 58.5% | 18.4% | 51.3% | 145.6% | 49.4% | |
| 0.5% | -65.1% | 21,710.3% | 286.0% | -147.7% | 974.8% | 46.0% | 19.9% | 4.5% | – | – | – | |
| 110.1% | -58.8% | -31.1% | 29.4% | -72.5% | -37.0% | 6.2% | 8.5% | 74.9% | -100.5% | -45.8% | -71.2% | |
| 7.0% | 9.2% | 266.4% | 67.9% | 19.3% | 9.8% | 3.3% | 7.4% | 1.3% | 5.6% | 2.9% | 0.0% | |
| -286.4% | 30.9% | -6,608.2% | 259.8% | -69.5% | 471.4% | -215.6% | -115.4% | -192.1% | 279.9% | 371.9% | 110.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 171.0% | 185.5% | 175.3% | 110.5% | – | – | – | – | |
| 404.5% | 578.4% | 42.5% | 461.0% | 1,146.6% | 314.6% | 1,254.6% | 1,249.0% | 28.1% | – | – | – | |
| 80.0% | 48.2% | 800.1% | -112.2% | -203.4% | – | – | – | – | – | – | – | |
| 404.5% | 578.4% | 842.5% | 460.7% | 942.4% | 623.1% | 1,254.6% | 1,249.0% | 81.5% | 168.9% | 842.6% | 40.6% | |
| 23.1% | 380.3% | -9,557.7% | 288.8% | -294.9% | -85.6% | 295.8% | 519.0% | -201.2% | -24.8% | 162.8% | -130.1% | |
| -89.8% | -229.5% | -4,125.4% | -522.1% | -1,170.1% | -1,191.1% | -747.3% | -622.0% | -91.9% | -479.3% | -1,053.8% | -281.5% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.